Minimal Residual Disease Analyzed by Flow Cytometry
スポンサーリンク
概要
- 論文の詳細を見る
Minimal residual disease (MRD) during chemotherapy has been applied to evaluate the response to the treatment, which is one of the most powerful predictors of relapse. In many strategies of MRD measurements, immunological MRD by flow cytometry is a very practical and widely applicable tool for monitoring MRD in patients with childhood acute lymphoblastic leukemia (ALL). This method is based on the identification of immunophenotypes expressed on only leukemic cells and not on normal hematopoietic cells in bone marrow or peripheral blood. It has already been reported that this method can identify 0.01% of leukemic cells, and is applicable to more than 90% of patients with childhood ALL. Because of a strong correlation between flow cytometric measurements of MRD during clinical remission and treatment outcome, recent treatment protocols in the United States or European countries have already applied MRD to choose the intensity of treatment protocols.<BR>Nevertheless, clinical application of MRD is still limited in the treatment protocols of childhood ALL in Japan. It is unquestionable we have to choose appropriate treatments proportional to the individual risk of relapse, which is provided by the measurements of MRD, immediately in Japan.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma